Posterior interscalene block-oral oxycodone
沙库巴曲缬沙坦联合达格列净对2_型糖尿病肾病患者的疗效分析
·糖尿病与并发症·糖尿病新世界 2024年2月DOI:10.16658/ki.1672-4062.2024.03.185沙库巴曲缬沙坦联合达格列净对2型糖尿病肾病患者的疗效分析李海东江苏如东洋口医院肾内科,江苏如东226407[摘要]目的探讨2型糖尿病肾病(Diabetic Nephropathy, DN)患者治疗中合用沙库巴曲缬沙坦与达格列净的临床疗效和对肾功能指标的影响。
方法选取2022年1月—2023年1月如东洋口医院收治的68例2型DN患者为研究对象,采用随机数表法分为对照组和观察组,每组34例。
对照组予以达格列净单一治疗,观察组予以达格列净和沙库巴曲缬沙坦联合治疗。
比较两组的临床疗效、肾功能指标、血糖变化及氧化应激指标。
结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。
治疗后,两组空腹血糖、糖化血红蛋白水平均呈下降趋势,且观察组下降更明显,差异有统计学意义(P均<0.05)。
治疗后,两组尿素氮、血肌酐、24 h尿蛋白定量均呈下降趋势,肾小球滤过率呈升高趋势,且观察组改变更明显,差异有统计学意义(P均< 0.05)。
治疗后,两组总抗氧化能力、超氧化物歧化酶、谷胱甘肽过氧化物酶呈升高趋势,且观察组升高幅度更大,差异有统计学意义(P均<0.05)。
结论合用沙布巴曲缬沙坦与达格列净,在2型DN患者治疗中可取得确切疗效,改善肾功能,并实现血糖的良好控制,减轻炎症反应,提高预后。
[关键词] 沙库巴曲缬沙坦;达格列净;2型糖尿病;肾病;肾功能[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062(2024)02(a)-0185-05Efficacy of Sacubactril Valsartan Combined with Dapagliflozin in Patients with Type 2 Diabetic NephropathyLI HaidongDepartment of Nephrology, Yangkou Hospital, Rudong, Jiangsu Province, 226407 China[Abstract] Objective To investigate the clinical efficacy and effect of sacubactril valsartan and dapagliflozin on renal function in patients with type 2 diabetic nephropathy (DN). Methods 68 patients with type 2 DN admitted to Yangkou Hospital of Rudong from January 2022 to January 2023 were selected as the study objects and were divided into con⁃trol group and observation group by random number table method, with 34 cases in each group. The control group was given single treatment of daglipzin, and the observation group was given combined treatment of daglipzin and sakuba⁃tril valsartan. The clinical effects, and renal function indexes, blood glucose changes, and oxidative stress indexes of the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, fasting plasma glucose (FPG) and glyeosylated hemoglobin A1c (HbA1c) in both groups decreased, and the increase were more significant in the ob⁃servation group, and the difference was statistically significant (all P<0.05). After treatment, blood urea nitrogen (BUN), serum creatinine (Scr) and 24-hour urinary protein quantity (24 hUTP) in both groups showed a decreasing trend, the glomerular filtration rate showed an increasing trend, and the change was more obvious in the observation group, and the difference was statistically significant (all P<0.05). After treatment, total antioxidant capacity (T-AOC), superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) in both groups showed an increasing trend, and the [作者简介]李海东(1976-),男,本科,主任医师,研究方向为肾小球肾炎、糖尿病肾病。
循证医学PICO
所有入选病例均接受全身化疗,方案以EP方案为主。其中57例(77%) 接受胸部放疗,58例(78.4%)接受预防性颅脑照hylactic cranial irradiation,PCI)。通过统计治疗后总有效率(CR+PR)及生存率对所 选病例进行分析。[结果]疗效评价按实体肿瘤的疗效评价标准 (Response EvaluationCriteria In Solid Tumors RECISTl.1)标准进行。 手术组总有效率(CR+PR):96.8%。非手术组总有效率:93.0%。1、 2、3年生存率为93.2%、85.1%、63.5%。手术组与非手术组1、2、3年 生存率分别为93.54%、87.09%、77.41%,93.02%、83.72%、55.82%, 手术组内观察:pI期、pIIa期、pIIb期1、2、3年生存率分别为:100%、 90.90%、90.90%,100%、88.88%、88.88%,81.81%、63.63%、 54.54%。手术组与非手术组1、2年生存率无明显差异,3年生存率手术 组优于非手术组(P<0.05)。手术组内分析:pI期~pIIa期生存率无差 异,IIb期生存率明显降低。差异有统计学意义(P<0.05)。[结论]在早 期小细胞肺癌患者治疗方案的选择中:单纯化、放疗相比,手术治疗联 合化疗或联合化疗+放疗的治疗手段,能明显延长小细胞肺癌患者生存 时间。肿瘤TN分期对早期小细胞肺癌的预后均有明显影响。
证据3
来源数据库:PubMed Journal DOI:10.3390/ijms160511439 关键词:CC chemokine ligand 2 (CCL2); SCLC; blood–brain barrier (BBB); brain metastasis; transendothelial migration; visfatin; 摘要:Small-cell lung cancer (SCLC) is characterized as an aggressive tumor with brain metastasis. Although preventing SCLC metastasis to the brain is immensely important for survival, the molecular mechanisms of SCLC cells penetrating the blood-brain barrier (BBB) are largely unknown. Herein, we present evidence that elevated levels of visfatin in the serum of SCLC patients were associated with brain metastasis, and visfain was increased in NCI-H446 cells, a SCLC cell line, during interacting with human brain microvascular endothelial cells (HBMEC). Using in vitro BBB model, we found that visfatin could promote NCI-H446 cells migration across HBMEC monolayer, while the effect was inhibited by knockdown of visfatin. Furthermore, our findings indicated that CC chemokine ligand 2 (CCL2) was involved in visfatin-mediated NCI-H446 cells transendothelial migtation. Results also showed that the upregulation of CCL2 in the co-culture system was reversed by blockade of visfatin. In particular, visfatin-induced CCL2 was attenuated by specific inhibitor of PI3K/Akt signaling in NCI-H446 cells. Taken together, we demonstrated that visfatin was a prospective target for SCLC metastasis to brain, and understanding the molecular mediators would lead to effective strategies for inhibition of SCLC brain metastasis.
噬菌体展示技术筛选脑靶向功能肽及其修饰纳米粒的脑内递药研究
噬菌体展示技术筛选脑靶向功能肽及其修饰纳米粒的脑内递药研究一、概述在生物医学领域中,脑靶向递药系统一直是研究的热点和难点。
由于血脑屏障的存在,许多药物难以有效进入大脑,从而限制了其在中枢神经系统疾病治疗中的应用。
开发新型的脑靶向递药技术,对于提高药物在脑部的浓度和疗效,降低副作用具有重要意义。
噬菌体展示技术以其独特的优势在药物研发和生物医学领域得到广泛应用。
该技术通过将外源蛋白或多肽的DNA序列插入到噬菌体外壳蛋白结构基因的适当位置,使外源基因随外壳蛋白的表达而表达,同时外源蛋白随噬菌体的重新组装而展示到噬菌体表面。
利用噬菌体展示技术,我们可以筛选到与特定靶标具有高亲和力的多肽或蛋白,为药物研发和疾病治疗提供新的候选分子。
本研究旨在利用噬菌体展示技术筛选具有脑靶向功能的多肽,并将其修饰到纳米粒表面,构建新型的脑靶向递药系统。
通过优化筛选条件和方式,我们成功获得了多个具有脑靶向功能的多肽序列,并通过实验验证了其脑靶向性。
我们还将这些多肽以共价连接的方式修饰到聚乙二醇聚乳酸羟基乙酸共聚物(PEGPLGA)纳米粒表面,以提高药物的稳定性和脑部递送效率。
本研究不仅为脑靶向递药系统的开发提供了新的思路和方法,还为中枢神经系统疾病的治疗提供了新的候选药物和递送策略。
通过进一步的研究和优化,我们相信这种新型的脑靶向递药系统将在未来为更多的患者带来福音。
1. 介绍脑靶向药物递送的重要性与挑战脑靶向药物递送是神经科学领域的一个关键研究方向,对于治疗脑部疾病具有重要意义。
由于血脑屏障的存在,许多药物难以有效穿透并进入脑组织,这使得脑内疾病的治疗面临着巨大的挑战。
开发高效的脑靶向药物递送系统成为当前研究的热点和难点。
脑靶向药物递送的重要性主要体现在以下几个方面:对于脑部疾病如阿尔茨海默病、帕金森病、脑肿瘤等,有效的药物递送能够显著提高治疗效果,改善患者的生存质量。
脑靶向递送系统能够实现药物的精准定位,减少对其他组织器官的副作用。
超声引导下微波消融联合贝伐珠单抗治疗晚期结肠癌伴肝转移的临床价值
·临床研究·超声引导下微波消融联合贝伐珠单抗治疗晚期结肠癌伴肝转移的临床价值韩小军袁理郭道宁摘要目的探讨超声引导下微波消融联合贝伐珠单抗治疗晚期结肠癌伴肝转移的临床应用价值。
方法选取在我院就诊的102例晚期结肠癌伴肝转移患者,按随机数字表法分为观察组和对照组各51例,对照组采用贝伐珠单抗联合常规化疗治疗,观察组在此基础上采用超声引导下微波消融治疗;比较两组患者治疗后疗效、免疫功能、不良反应及预后情况。
结果治疗后,观察组客观缓解率(ORR)、疾病控制率(DCR)均高于对照组(均P<0.05);两组CD3+、CD4+、CD8+均较治疗前下降,且观察组CD3+、CD4+、CD4+/CD8+均高于对照组,CD8+低于对照组,差异均有统计学意义(均P<0.05)。
治疗后,两组胃肠道反应、食欲减退、疲劳乏力等不良反应比较差异均无统计学意义;观察组累积无复发生存率及累积总生存率分别为78.77%、57.45%,均高于对照组(49.32%、34.23%),差异均有统计学意义(χ2=10.086、4.536,P=0.001、0.033)。
结论超声引导下微波消融联合贝伐珠单抗能提高晚期结肠癌伴肝转移患者的治疗效果,缓解免疫功能抑制,改善生存状况,具有较好的临床应用价值。
关键词超声引导;微波消融;结肠癌,晚期;肝转移;贝伐珠单抗[中图法分类号]R445.1[文献标识码]AClinical value of ultrasound-guided microwave ablation combined withbevacizumab in the treatment of advanced colonadenocarcinoma with liver metastasisHAN Xiaojun,YUAN Li,GUO DaoningDepartment of Ultrasound Medicine,Mianyang Hospital Affiliated to School of Medicine,University of Electronic Science andTechnology of China,Sichuan621000,ChinaABSTRACT Objective To explore the application clinical value of ultrasound-guided microwave ablation combined with bevacizumab in the treatment of advanced colon adenocarcinoma(COAD)with liver metastasis.Methods A total of102 patients with advanced COAD with liver metastasis treated in our hospital were selected,and divided into the observation group and the control group by random number table method,with51cases in each group.The control group was treated with bevacizumab combined with conventional chemotherapy.On this basis,the observation group was treated with ultrasound-guided microwave thermal ablation.The curative effect,immune function,adverse reactions and prognosis after treatment of the two groups were compared.Results After treatment,the objective remission rate(ORR)and disease control rate(DCR)in the observation group were higher than those in the control group(both P<0.05).After treatment,the CD3+,CD4+and CD4/CD8+in the observation group were higher than those in the control group,and CD8+was lower than that in the control group,the differences were statistically significant(all P<0.05).After treatment,there were no statistically significant difference in the incidence rates of adverse reactions such as gastrointestinal reactions,loss of appetite and fatigue between the two groups.The cumulative recurrence-free survival rate and cumulative overall survival rate in observation group were78.77%and57.45% respectively,which were significantly higher than those in control group(49.32%and34.23%),the differences were statistically significant(χ2=10.086,4.536,P=0.001,0.033).Conclusion Ultrasound-guided microwave ablation combined with作者单位:621000四川省绵阳市,电子科技大学医学院附属绵阳医院绵阳市中心医院超声医学科(韩小军、郭道宁),肿瘤科(袁理)通讯作者:郭道宁,Email:******************结肠癌是常见的消化道肿瘤,近年来其发病率和死亡率均逐渐升高。
细胞培养用青霉素-链霉素产品说明书
细胞培养用青霉素-链霉素产品简介:细胞培养用青霉素-链霉素(Penicillin-Streptomycin for Cell Culture)为粉剂,是最常用的细胞培养用抗生素(即通常所谓的双抗)。
在细胞培养液中推荐的青霉素的工作浓度为100U/ml ,链霉素的工作浓度为0.1mg/ml 。
一个包装的细胞培养用青霉素-链霉素可以配制80L 细胞培养液。
保存条件:室温保存。
4ºC 保存可以使用更长时间。
注意事项:开瓶后需防止受潮。
本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
为了您的安全和健康,请穿实验服并戴一次性手套操作。
使用说明:细胞培养用青霉素-链霉素可以参考如下两种方法之一使用:1. 配制细胞培养液时加入细胞培养用青霉素-链霉素,然后再过滤除菌:配制细胞培养液时按照青霉素的工作浓度为100U/ml ,链霉素的工作浓度为0.1mg/ml 进行配制,配制完成后过滤除菌即可使用。
2. 配制青霉素-链霉素溶液(100X)母液,然后再添加到细胞培养液中:按照青霉素的含量为10KU/ml ,链霉素的含量为10mg/ml ,配制青霉素-链霉素溶液(100X)母液。
过滤除菌后即可按照100倍稀释加入到细胞培养液中使用。
配制的母液可以-20ºC 冻存。
使用本产品的文献:1. Wang PH, Gu ZH, Wan DH, Zhang MY , Weng SP, Yu XQ, He JG. The shrimp NF-κB pathway is activated by white spot syndrome virus (WSSV) 449 to facilitate the expression of WSSV069 (ie1), WSSV303 and WSSV371.PLoS One. 2011;6(9):e24773.2. Xia M, Zhu Y . Signaling pathways of ATP-induced PGE2 release inspinal cord astrocytes are EGFR transactivation-dependent. Glia. 2011 Apr;59(4):664-74. 3. He YH, Song Y , Liao XL, Wang L, Li G, A lima, Li Y , Sun CH. Thecalcium-sensing receptor affects fat accumulation via effects on antilipolytic pathways in adipose tissue of rats fed low-calcium diets. J N utr. 2011 Nov;141(11):1938-46. 4. Liu XY , Wei W, Wang CL, Yue H, Ma D, Zhu C, Ma GH, Du YGApoferritin-camouflaged Pt nanoparticles: surface effects on cellular uptake and cytotoxicity. J. Mater. Chem., 2011,21, 7105-7110. 5. Wang MN, Liu XY , Cao CB, Shi C Synthesis of band-gap tunable Cu –In –S ternary nanocrystals in aqueous solution RSC Adv. 2012 Feb; 7:2666-70. 6. Fan H, Yang L, Fu F, Xu H, Meng Q, Zhu H, Teng L, Yang M, Zhang L,Zhang Z, Liu K Cardio protective effects of salvianolic Acid a on myocardial ischemia-reperfusion injury in vivoand in vitro. Evid Based Complement Alternat Med. 2012;2012:508938. 7. Zhang J, Tang L, Shen L, Zhou S, Duan Z, Xiao L, Cao Y , Mu X, Zha L,Wang H High level of WA VE1 expression is associated with tumor aggressiveness and unfavorableprognosis of epithelial ovarian cancer. Gynecol Oncol. 2012 Oct;127(1):223-30.8. Zhang Y , Zhang Y , Chen M, Yan J, Ye Z, Zhou Y , Tan W, Lang M.Surface properties of amino-functionalized poly(ε-caprolactone) membranes and the improvement of humanmesenchymal stem cell behavior. J Colloid Interface Sci. 2012 Feb 15;368(1):64-9. 9. Jiang M, Gan L, Zhu C, Dong Y , Liu J, Gan Y . Cationic core-shellliponanoparticles for ocular gene delivery. Biomaterials. 2012 Oct; 33(30):7621-30. 10. Chai YY , Wang F, Li YL, Liu K, Xu H. Antioxidant Activities ofStilbenoids from Rheum emodi Wall. Evid Based Complement Alternat Med. 2012;2012:603678. 11. Guo S, Sun X, Cheng J, Xu H, Dan J, Shen J, Zhou Q, Zhang Y , Meng L,Cao W, Tian Y . Apoptosis of THP-1 macrophages induced by protoporphyrin IX-mediated sonodynamic therapy. Int J Nanomedicine. 2013;8:2239-46. 12. Wang S, Luo Y , Zeng S, Luo C, Yang L, Liang Z, Wang Y .Dodecanol-poly(D,L-lactic acid)-b-poly (ethylene glycol)-folate (Dol- PLA-PEG-FA) nanoparticles: evaluation of cell cytotoxicity and selecting capability in vitro. Colloids Surf B Biointerfaces. 2013 Feb 1;102:130-5.碧云天生物技术/Beyotime Biotechnology 订货热线: 400-1683301或800-8283301 订货e-mail :****************** 技术咨询: ***************** 网址: 碧云天网站 微信公众号13.Zhou S, Tang L, Wang H, Dai J, Zhang J, Shen L, Ng SW, Berkowitz RS.Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer. Gynecol Oncol. 2013 Oct;131(1):69-76.14.Xia M, Zhu Y. FOXO3a Involvement in the Release of TNF-α Stimulatedby ATP in Spinal Cord Astrocytes. J Mol Neurosci. 2013 Nov;51(3):792-804.15.Zhou DH, Wang X, Yang M, Shi X, Huang W, Feng Q. Combination ofLow Concentration of (-)-Epigallocatechin Gallate (EGCG) and Curcumin Strongly Suppresses the Growth of Non-Small Cell Lung Cancer in Vitro and in Vivo through Causing Cell Cycle Arrest. Int J Mol Sci. 2013 Jun 5;14(6):12023-36.16.Jiang XY, Lu DB, Jiang YZ, Zhou LN, Cheng LQ, Chen B.PGC-1αprevents apoptosis in adipose-derived stem cells by reducing reactive oxygen species production in adiabetic microenvironment. Diabetes Res Clin Pract. 2013 Jun;100(3):368-75.17.Zhu Q, Guo T, Xia D, Li X, Zhu C, Li H, Ouyang D, Zhang J, Gan Y.Pluronic F127-modified liposome-containing tacrolimus-cyclodextrin inclusion complexes: improved solubility, cellular uptake and intestinal penetration.J Pharm Pharmacol. 2013 Aug;65(8):1107-17.18.Hu HJ, Lin XL, Liu MH, Fan XJ, Zou WW. Curcumin mediatesreversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Metexpression in DU145 cells. Oncol Lett. 2016 Feb;11(2):1499-1505.19.Sun C, Feng SB, Cao ZW, Bei JJ, Chen Q, Zhao WB, Xu XJ, Zhou Z, YuZP, Hu HY. Up-Regulated Expression of Matrix Metalloproteinases in Endothelial Cells Mediates PlateletMicrovesicle-Induced Angiogenesis.CELL PHYSIOL BIOCHEM . 2017;41(6):2319-2332.20.Wang J, Zeng H, Li H, Chen T, Wang L, Zhang K, Chen J, Wang R, Li Q,Wang S. MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of BreastCancer Cells by Targeting Sex-Determining Region Y-Box 2. CELL PHYSIOL BIOCHEM .2017;43(2):717-732.21.Jiang W, Huang W, Chen Y, Zou M, Peng D, Chen D. HIV-1Transactivator Protein Induces ZO-1 and Neprilysin Dysfunction in Brain Endothelial Cellsvia the Ras Signaling Pathway. Oxid Med Cell Longev . 2017;2017:3160360.22.Li W, Yang Y, Ba Z, Li S, Chen H, Hou X, Ma L, He P, Jiang L, Li L, HeR, Zhang L, Feng D. MicroRNA-93 Regulates Hypoxia-Induced Autophagy by Targeting ULK1. Oxid Med Cell Longev .2017;2017:2709053.23.Hu SY, Zhang Y, Zhu PJ, Zhou H, Chen YD. Liraglutide directly protectscardiomyocytes against reperfusion injury possibly via modulation of intracellular calcium homeostasis. J Geriatr Cardiol . 2017 Jan;14(1):57-66.24.Li W, Wang Z, Zha L, Kong D, Liao G, Li H. HMGA2 regulatesepithelial-mesenchymal transition and the acquisition of tumor stem cellproperties through TWIST1 in gastric cancer. Oncol Rep . 2017 Jan;37(1):185-192.25.Tang J, Dong Q. Knockdown of TREM-1 suppresses IL-1β-inducedchondrocyte injury via inhibiting the NF-κB pathway. BIOCHEM BIOPH RES CO . 2017 Jan 22;482(4):1240-1245.26.Yang T, Cheng J, Yang Y, Qi W, Zhao Y, Long H, Xie R, Zhu B. S100BMediates Stemness of Ovarian Cancer Stem-Like Cells Through Inhibiting p53. Stem Cells . 2017 Feb;35(2):325-336.27.Sun K, Liu F, Wang J, Guo Z, Ji Z, Yao M. The effect of mechanicalstretch stress on the differentiation and apoptosis of human growthplate chondrocytes. IN VITRO CELL DEV-AN . 2017 Feb;53(2):141-148. 28.Peng L, Wang R, Shang J, Xiong Y, Fu Z. Peroxiredoxin 2 is associatedwith colorectal cancer progression and poor survival of patients.ONCOTARGET . 2017 Feb 28;8(9):15057-15070.29.Li L, Guan Q, Dai S, Wei W, Zhang Y. Integrin β1 Increases Stem CellSurvival and Cardiac Function after Myocardial Infarction. Front Pharmacol . 2017 Mar 17;8:135.30.Sui Y, Yao H, Li S, Jin L, Shi P, Li Z, Wang G, Lin S, Wu Y, Li Y, HuangL, Liu Q, Lin X. Delicaflavone induces autophagic cell death in lung cancer via Akt/mTOR/p70S6K signalingpathway. J MOL MED . 2017 Mar;95(3):311-322.31.Zuo S, Ge H, Li Q, Zhang X, Hu R, Hu S, Liu X, Zhang JH, Chen Y,Feng H. Artesunate Protected Blood-Brain Barrier via Sphingosine 1 Phosphate Receptor1/Phosphatidylinositol 3 Kinase Pathway After Subarachnoid Hemorrhage in Rats. Mol Neurobiol . 2017 Mar;54(2):1213-1228.32.Shen XQ, Geng YM, Liu P, Huang XY, Li SY, Liu CD, Zhou Z, Xu PP.Magnitude-dependent response of osteoblasts regulated by compressive stress. SCI REP-UK . 2017 Mar 20;7:44925.33.Yang R, Wei L, Fu QQ, You H, Yu HR. SOD3 Ameliorates Aβ25-35-Induced Oxidative Damage in SH-SY5Y Cells by Inhibiting the Mitochondrial Pathway. Cell Mol Neurobiol . 2017 Apr;37(3):513-525.34.Lin H, Zhao L, Ma X, Wang BC, Deng XY, Cui M, Chen SF, Shao ZW.Drp1 mediates compression-induced programmed necrosis of rat nucleus pulposus cells by promoting mitochondrial translocation of p53 and nuclear translocation of AIF. BIOCHEM BIOPH RES CO . 2017 May 20;487(1):181-188.35.Zhang C, Zhou G, Cai C, Li J, Chen F, Xie L, Wang W, Zhang Y, Lai X,Ma L. Human umbilical cord mesenchymal stem cells alleviate acute myocarditis by modulatingendoplasmic reticulum stress and extracellular signal regulated 1/2-mediated apoptosis. Mol Med Rep . 2017 Jun;15(6):3515-3520.36.Zhang EF, Hou ZX, Shao T, Yang WW, Hu B, Wang XX, Zhang ZX,Huang Y, Xiong LZ, Hou LC. Combined administration of a sedative dose sevoflurane and 60% oxygen reduces inflammatoryresponses to sepsis in animals and in human PMBCs. Am J Transl Res . 2017 Jun 15;9(6):3105-3119.37.Shi S, Zhong D, Xiao Y, Wang B, Wang W, Zhang F, Huang H.Syndecan-1 knockdown inhibits glioma cell proliferation and invasion by deregulating a c-src/FAK-associated signaling pathway.ONCOTARGET . 2017 Jun 20;8(25):40922-40934.38.Lin XL, Hu HJ, Liu YB, Hu XM, Fan XJ, Zou WW, Pan YQ, Zhou WQ,Peng MW, Gu CH. Allicin induces the upregulation of ABCA1 expression via PPARγ/LXRαsignaling in THP-1macrophage-derived foam cells. Int J Mol Med . 2017 Jun;39(6):1452-1460.39.Peng K, Yang L, Wang J, Ye F, Dan G, Zhao Y, Cai Y, Cui Z, Ao L, Liu J,Zou Z, Sai Y, Cao J. The Interaction of Mitochondrial Biogenesis and Fission/Fusion Mediated by PGC-1αRegulatesRotenone-Induced Dopaminergic Neurotoxicity. Mol Neurobiol . 2017 Jul;54(5):3783-3797.40.Liu Z, Zeng W, Wang S, Zhao X, Guo Y, Yu P, Yin X, Liu C, Huang T. Apotential role for the Hippo pathway protein, YAP, in controlling proliferation, cell cycleprogression, and autophagy in BCPAP and KI thyroid papillary carcinoma cells. Am J Transl Res . 2017 Jul 15;9(7):3212-3223.41.Ge Z, Diao H, Yu M, Ji X, Liu Q, Chang X, Wu Q. Connexin 43mediates changes in protein phosphorylation in HK-2 cells during chronic cadmiumexposure. ENVIRON TOXICOL CHEM . 2017 Jul;53:184-190.42.Zhu YM, Gao X, Ni Y, Li W, Kent TA, Qiao SG, Wang C, Xu XX, ZhangHL. Sevoflurane postconditioning attenuates reactive astrogliosis and glial scar formation afterischemia-reperfusion brain injury.Neuroscience . 2017 Jul 25;356:125-141.43.Wei JL, Fang M, Fu ZX, Zhang SR, Guo JB, Wang R, Lv ZB, Xiong YF.Sestrin 2 suppresses cells proliferation through AMPK/mTORC1 pathway activation in colorectalcancer. ONCOTARGET . 2017 Jul 25;8(30):49318-49328.44.Zhao L, Yang Y, Yin S, Yang T, Luo J, Xie R, Long H, Jiang L, Zhu B.CTCF promotes epithelial ovarian cancer metastasis by broadly controlling the expression of metastasis-associated genes.ONCOTARGET . 2017 Jul 10;8(37):62217-62230.45.Fu QQ, Wei L, Sierra J, Cheng JZ, Moreno-Flores MT, You H, Y u HR.Olfactory Ensheathing Cell-Conditioned Medium Reverts Aβ25-35-Induced Oxidative Damage in SH-SY5Y Cells by Modulating the Mitochondria-Mediated Apoptotic Pathway. Cell Mol Neurobiol . 2017 Aug;37(6):1043-1054.46.Wang T, Liu YP, Wang T, Xu BQ, Xu B. ROS feedback regulates themicroRNA-19-targeted inhibition of the p47phox-mediated LPS-induced inflammatory response. BIOCHEM BIOPH RES CO . 2017 Aug 5;489(4):361-368.47.Zhu Y, Wang L, Y u H, Yin F, Wang Y, Liu H, Jiang L, Qin J. In situgeneration of human brain organoids on a micropillar array. Lab Chip .2017 Aug 22;17(17):2941-2950.48.Liu C, Liu J, Hao Y, Gu Y, Yang Z, Li H, Li R.6,7,3',4'-Tetrahydroxyisoflavone improves the survival of whole-body-irradiated mice viarestoration of hematopoietic function. Int J Radiat Biol . 2017 Aug;93(8):793-802.49.Liao Q, Zhang R, Wang X, Nian W, Ke L, Ouyang W, Zhang Z. Effect offluoride exposure on mRNA expression of cav1.2 and calcium signal pathway apoptosisregulators in PC12 cells. ENVIRON TOXICOL CHEM . 2017 Sep;54:74-79.2 / 3ST488 细胞培养用青霉素-链霉素400-1683301/800-8283301碧云天/Beyotime50.Pan S, Cui Y, Dong X, Zhang T, Xing H. MicroRNA-130b attenuatesdexamethasone-induced increase of lipid accumulation in porcinepreadipocytes by suppressing PPAR-γexpression.ONCOTARGET . 2017 Sep 27;8(50):87928-87943.51.Zhong Y, Jin C, Gan J, Wang X, Shi Z, Xia X, Peng X. Apigeninattenuates patulin-induced apoptosis in HEK293 cells by modulating ROS-mediatedmitochondrial dysfunction and caspase signal pathway.Toxicon . 2017 Oct;137:106-113.52.Yin L, Huang D, Liu X, Wang Y, Liu J, Liu F, Yu B. Omentin-1 effectson mesenchymal stem cells: proliferation, apoptosis, and angiogenesis in vitro. Stem Cell Res Ther . 2017 Oct 10;8(1):224.53.Tang X, Zha L, Li H, Liao G, Huang Z, Peng X, Wang Z. Upregulationof GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway. Oncol Rep . 2017 Oct;38(4):2023-2032.54.Wu S, Wu F, Jiang Z. Identification of hub genes, key miRNAs andpotential molecular mechanisms of colorectalcancer. Oncol Rep . 2017 Oct;38(4):2043-2050.55.Wang X, Chen G, Huang C, Tu H, Zou J, Yan J. Bone marrow stemcells-derived extracellular matrix is a promising material.ONCOTARGET . 2017 Oct 9;8(58):98336-98347.56.Sun R, Yin L, Zhang S, He L, Cheng X, Wang A, Xia H, Shi H. SimpleLight-Triggered Fluorescent Labeling of Silica Nanoparticles for Cellular ImagingApplications. Chemistry . 2017 Oct 9;23(56):13893-13896. 57.Lin H, Ma X, Wang BC, Zhao L, Liu JX, Pu FF, Hu YQ, Hu HZ, ShaoZW. Edaravone ameliorates compression-induced damage in rat nucleus pulposus cells. Life Sci . 2017 Nov 15;189:76-83.58.Sun G, Sui X, Han D, Gao J, Liu Y, Zhou L. TRIM59 promotes cellproliferation, migration and invasion in human hepatocellular carcinomacells. Pharmazie . 2017 Nov 1;72(11):674-679.59.Zhu Y, Wang L, Yin F, Yu Y, Wang Y, Shepard MJ, Zhuang Z, Qin J.Probing impaired neurogenesis in human brain organoids exposed to alcohol. INTEGR BIOL-UK . 2017 Dec 11;9(12):968-978.60.Shan Y, Wang Y, Li J, Shi H, Fan Y, Yang J, Ren W, Y u X. Biomechanicalproperties and cellular biocompatibility of 3D printed tracheal graft.Bioprocess Biosyst Eng . 2017 Dec;40(12):1813-1823.61.Liu H, Wu B, Ge Y, Huang J, Song S, Wang C, Yao J, Liu K, Li Y, Li Y,Ma X. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesionkinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines. BIOORG MED CHEM LETT . 2017 Dec 15;25(24):6313-6321.62.Lin XL,Liu M,Liu Y,Hu H,Pan Y,Zou W,Fan X,Hu X. Transforminggrowth factor β1 promotes migration and invasion in HepG2 cells: Epithelial-to-mesenchymal transition via JAK/STA T3 signaling. Int J Mol Med. 2018 Jan;41(1):129-136.63.Duan C,Liu Y,Li Y,Chen H,Liu X,Chen X,Y ue J,Zhou X,Yang J.Sulfasalazine alters microglia phenotype by competing endogenous RNA effect of miR-136-5p and long non-coding RNA HOTAIR in cuprizone-induced demyelination. Biochem Pharmacol. 2018 Sep;155:110-123.64.Zhou X,Li T,Chen Y,Zhang N,Wang P,Liang Y,Long M,Liu H,Mao J,LiuQ,Sun X,Chen H. Mesenchymal stem cell-derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway. Int J Oncol. 2019 May;54(5):1843-1852.65.Zheng W,Liu C. The cystathionine γ-lyase/hydrogen sulfide pathwaymediates the trimetazidine-induced protection of H9c2 cells against hypoxia/reoxygenation-induced apoptosis and oxidative stress. Anatol J Cardiol. 2019 Sep;22(3):102-111.66.Lou K,Huang P,Ma H,Wang X,Xu H,Wang W. Orlistat increases arsenitetolerance in THP-1 derived macrophages through the up-regulation of ABCA1. Drug Chem Toxicol. 2019 Oct 31:1-9.67.Liang S,Wang F,Bao C,Han J,Guo Y,Liu F,Zhang Y. BAG2 amelioratesendoplasmic reticulum stress-induced cell apoptosis in Mycobacterium tuberculosis-infected macrophages through selective autophagy.Autophagy. 2019 Nov 11:1-15.68.Yuan K,Lai C,Wei L,Feng T,Yang Q,Zhang T,Lan T,Yao Y,XiangG,Huang X. The Effect of Vascular Endothelial Growth Factor on Bone Marrow Mesenchymal Stem Cell Engraftment in Rat Fibrotic Liver upon Transplantation. Stem Cells Int. 2019 Dec 4;2019:5310202.Version 2021.11.04碧云天/Beyotime 400-1683301/800-8283301 ST488 细胞培养用青霉素-链霉素 3 / 3。
手术室无菌概念和无菌操作(铺单 消毒 穿戴手术衣等)
在感染源的危险。
Committed to Innovation
1、目的 保证手术室的灭菌区域,每一位在
手术室的人都有责任执行灭菌操作.灭 菌操作在术前、术中和术后都要严格执 行,以减少污染机会。
Committed to Innovation
Committed to Innovation
• 刷洗顺序:指尖→手→腕→前臂→肘部到上臂 下1/2段
• 刷洗方法:每遍刷完后,用流水冲去肥皂沫, 水由手、上臂至肘部淋下,手不能放在最低位, 以免手部的水返流到手刷,洗毕用无菌小毛巾 依次拭干不可触碰其它物品
• 刷洗时限无遗漏地刷洗三遍,每遍3分钟。 特别提示:要刷净甲沟、指间、腕部
32
(3)将手术衣向上轻轻抛起,双手顺势 插入袖中,两臂前伸,不可高举过肩,也 不可向左右侧撒开,以免触碰污染。
(4)系腰带:松开腰带,将腰带一端交 于巡回护士,原地旋转,将左右两端系于 腰前。
33
3、连台手术更换手术衣
手术完毕,若需进行另一台手术时, 必须更换手术衣及手套。先由巡回护士解 开腰带及领口系带,再由他人帮助或自行 脱下手术衣,最后脱去手套。
5. 无菌物品要用无菌持物钳取,无菌物品一经取 出后,即不能再放回无菌容器内。
6. 拿取无菌物品时要面向无菌区,手臂必须保持 在自己腰部水平,或桌面以上,不可过低。
7. 不可面向无菌区大声谈笑、咳嗽、打喷嚏,不
能控制时应扭转头位。
Committed to Innovation
手术室的结构、功能特点决定 了它与病房的不同,因此进入手术 室必须遵守手术室的着装要求,并 严格规范各项无菌操作,防止术后 感染的发生。
心血管英文单词
心力衰竭:Heart failure心力衰竭Con gestive beart failure 充血性心力衰竭Acute left-sided heart failure 急性左心衰竭Chroinc heart failure 慢性心力衰竭In tractable heart failure 难治性心力衰竭Systolic in sufficie ncy heart failure 收缩功能不全性心力衰竭Diastolic in sufficie ncy heart failure 舒张功能不全性心力衰竭Con gestive heart failure 充血性心力衰竭Cardiac dysfunction 心功能障碍心律失常:Arrhythmia ( cardiac arrhythmia )心律失常Triggered activity 触发活动Afterdepolarization 后除极a. 窦房结Si nus n ode recovery time SNRT 窦房结恢复时间Sino atrial co nduction time SACT 窦房传导时间Bradycardia心动过缓Tachycardia心动过速Sinus tachycardia窦性心动过速Sinus bradycardia窦性心动过缓Si nus pause (si nus arrest) 窦性停搏(窦性静止)sinoatrial block 窦房阻滞(Mobitz 莫氏,Wenckebach 文氏) Sick sin us syndrome(SSS) 病(态)窦(房结)综合征Bradycardia-tachycardia syn drome 心动过缓-心动过速综合征b. 心房Atrial premature beats 房性期前收缩Atrial tachycardia房性心动过速In tri nsic heart rate 固有心率Automatic atrial tachycardia 自律性房性心动过速Ree ntra nt atrial tachycardia 折返性房性心动过速Chaotic atrial tachycardia 紊乱性房性心动过速Paroxysmal atrial tachycardia with AV block (PAT with block) 阵发性房性心动过速伴有房室阻滞的Multifocal atrial tachycardia 多源性房性心动过速Atrial flutter 心房扑动Atrial fibrillation 心房颤动c. 房室交界区性Premature atriove ntricular junctional beats 房室交界区性期前收缩AV jun ctio nal escape beats 房室交界区性逸搏AV jun ctio nal rhythm房室交界区性心律Non paroxysmal atriove ntricular j un cti onal tachycardia 非阵发性房室交界区性心动过速Paroxysmal suprave ntricular tachycardia(PSVT)阵发性室上性心动过速Atriove ntricular Nodal Ree ntra nt Tachycardia(AVNRT) 房室结内折返性心动过速Atriove ntricular Ree ntra nt Tachycardia(AVNRT)房室返性心动过速Preexcitation syndrome(Wolff-Parkinson-White syndrome) 预激综合征(WPW 综合征)d. 心室Premature ven tricular beats 室性期前收缩Ven tricular parasystole 室性并行心律Ven tricular tachycardia 室性心动过速Accelerated idiove ntricular rhythm 加速性心室自主节律Torsades de poin tes 尖端扭转Ventricular flutter 心室扑动Ve ntricular fibrillati on 心室颤动Atrioventricular block 房室传导阻滞Wenckebach block 文氏阻滞Adame-Strokes syndrom 阿—斯综合征Intraventricular block 室内传导阻滞Right bun dle branch block 右束支传导阻滞Left bun dle branch block 左束支传导阻滞Left an terior fascicular block 左前分支传导阻滞Left posterior fascicular block 左后分支传导阻滞Bifascicular block 双分支阻滞Trifascicular block 三分支阻滞心脏骤停与猝死sudde n cardiac death 心脏性猝死Cardiac arrest 心脏骤停Pulseless electrical activity (PEA) 无脉性电活动高血压:Hypertension 高血压Hyperte nsive urge ncyes 高血压急症Hypertensive crisis 高血压危象Hyperte nsive emerge ncies 高血压危症Secondary hyperte nsion 继发性高血压Primary hyperte nsion 原发性高血压“ White coat ” hypertensiOh大衣性高血压4Isolated systolic hyperte nsion 单纯收缩期高血压Arteriolosclerosis 小动脉硬化先心病:Congen ital heart disease 先天性心脏病Congenital cardiovascular disease 先天性心血管病Pulm on ic ste no sis 肺动脉狭窄Isolated pulm on ic ste no sis 单纯肺动脉口狭窄Coarctati on of the aorta 主动脉缩窄Idiopathic dilatati on of the pul monary artery 单纯肺动脉扩张Primary pul monary hyperte nsion 原发性肺动脉高压Persiste nt left superior vena cava 双侧上腔静脉(左上腔静脉残存) Isolated dextrocardia 孤立性右位心Atrial septal defect 房间隔缺损Partial ano malous pul monary venous drain age 咅E分性肺静脉畸形引流Ven tricular septal defect (VSD) 室间隔缺损Eisenmenger ' s syndrome艾森门格综合征Pate nt ductus arteriosus(PDA) 动脉导管未闭Tetralogy of Fallot 法洛四联症Trilogy of Fallot法洛三联症Complete tran spositi on of the great vessels 完全性大血管错位Atrial septal defect (ASD) 房间隔缺损心脏瓣膜病:Multivalve heart disease 多瓣膜疾病5Mitral valve disease 二尖瓣疾病Pul monic valve disease 肺动脉瓣疾病Tricuspid valve disease 三尖瓣疾病Ebstein ' a s omaly三尖瓣下移畸形Dysfun cti on or rupture of papillary muscle 孚L头肌功能失调或断裂Aortic valve disease 主动脉瓣疾病Aortic arch syn drome 主动脉弓综合征Valvular heart disease 心脏瓣膜病rheumatic heart disease 风湿性心脏病Rheumatic fever 风湿热Rheumatic carditis风湿性心脏炎Mitral stenosis 二尖瓣狭窄Mitral in compete nee 二尖瓣关闭不全Acute mitral in sufficie ncy 急性二尖瓣关闭不全Chro nic mitral in sufficie ncy 慢性二尖瓣关闭不全Marfan ' s syndrom马凡氏综合征Aortic stenosis主动脉瓣狭窄Aortic in compete nee 主动脉瓣关闭不全Chro nic aortic in sufficie ncy 慢性主动脉瓣关闭不全Tricuspid ste no sis 三尖瓣狭窄Tricuspid in compete nee 三尖瓣关闭不全Pulmonary stenosis肺动脉瓣狭窄Pulm onary in compete nee 肺动脉瓣关闭不全冠心病:Atherosclerosis 动脉粥样硬化Coro nary atherosclerotic heart disease 冠状动脉粥样硬化性心脏病Coro nary heart disease 冠状动脉性心脏病Angina pectoris 心绞痛Stable angina pectoris 稳定型心绞痛Un stable angina pectoris 不稳定心绞痛In itial on set angina pectoris 初发型心绞痛Accelerated angina pectoris 恶化型心绞痛Variant angina pectoris (Prinzmetal ' s variant angina pe变t异型)心绞痛Angina decubitus卧位心绞痛Acute coronary in sufficie ncy 急性冠状动脉功能不全Posti nfarctio n angina pectoris 梗塞后心绞痛Acute coronary syn drome(ACS) 急性冠脉综合征Myocardial in farctio n(MI)心肌梗死Acute myocardial in farctio n(AMI) 急性心肌梗死Dysfunction of papillary muscle 孚L头肌功能失调Rupture of papillary muscle 孚L头肌断裂Rupture of the heart 心脏破裂Embolism 栓塞Cardiac aneurysm 心脏室壁瘤Posti nfarctio n syn drome 心肌梗死后综合征Late nt coro nary heart disease 无症状型冠心病(隐性冠心病) Ischemic cardiomyopathy 缺血性心肌病Sudden death 猝死感染性心内膜炎:In fective en docarditis (IE) 感染性心内膜炎Native valve en docarditis 自体瓣膜心内膜炎Prothetic valve en docarditis 人工瓣膜心内膜炎En docarditis in in trave nous drug abusers 静脉药瘾者心内膜炎Acute in fective en docarditics(AIE) 急性感染性心内膜炎Subacute In fective en docarditis 亚急性感染性心内膜炎心肌疾病:Specific cardiomyopathy 特异性心肌病Viral myocarditis病毒性心肌炎Hypertrophic cardiomyopathy ( HCM)肥厚性心肌病Asymmetric septal hypertrophy (ASH) 非对称性室间隔肥厚Restrictive cardiomyopathy(RCM)限制性心肌病Dilated cardiomyopathy ( DCM )扩张型心肌病Alcoholic cardiomyopathy 酒精性心肌病Peripartum cardiomyopathy 围生期心肌病Drug-i nduced cardiomyopathy 药物性心肌病Keshan disease (KD) 克山病En demic cardiomyopathy (ECD)地方性心肌病Cardiomyopathies 心肌疾病Myocardial bridging 心肌桥Myocarditis 心肌炎Right ven tricular cardiomyopathy 右室心肌病Arrhythmoge nic right ve ntricular cardiomyopathy(ARVC) 致心律失常型右室心肌病Un classified cardiomyopathies,UCM)心包疾病:Purulent pericarditis 化脓性心包炎Acute pericarditis 急性心包炎Tuberculous pericarditis 结核性心包炎Constrictive pericarditis 缩窄性心包炎血管疾病:Peripheral arteriosclerosis obliteratio n 闭塞性周围动脉粥样硬化Primary arteritis of the aorta and its ma in bran ches 多发性大动脉炎Raynaud syndrome 雷诺综合征Pulness disease 无脉病Thromboa ngitis oblitera ns 血栓闭塞性脉管炎Thrombophlebitis血栓性静脉炎Aortic dissect ion 主动脉夹层其它疾病:Syn drome XCardiogenic shock 心原性休克Postpericardiostomy syn drome 心肌损伤后综合征Pul monary embolism 肺动脉栓塞Syncope 晕厥Syphlitic cardiovascular disease 梅毒性心血管病Cardiovascular neurosis 心脏血管神经官能症药物Vasodilator血管扩张剂(phlebectasis静脉扩张,arteriectasis动脉扩张)Diuretic 利尿剂(thiazide diuretic 噻嗪类利尿剂;loop diuretic袢利尿剂;potassium-sparing diuretics 保钾利尿剂)in otropic age nt 正性肌力药(digitalis preparati on 洋地黄制剂;adre nergic receptor stimulant肾上腺素能受体兴奋剂;phosphodiesterase in hibitor 磷酸二酯酶抑制剂)Angiotensin converting enzyme inhibitor (ACE inhibitors)(ACEI )血管紧张素转换酶抑制剂Aldoster one an tago nist 醛固酮拮抗剂Beta adrenergic receptor blocker (beta blockers)?肾上腺素能受体阻滞剂Calcium cha nnel blocker (CCB)钙通道阻滞剂An giote nsion n an tag oni st(A ngiote nsion n receptor blocker)血管紧张素U 受体阻滞剂Alpha blockers a受体阻滞剂Nitroglycerin 硝酸甘油Digox in地高辛Lanatoside C 西地兰10antiarrhythic drugs 抗心律失常药lidocaine利多卡因Propafenone普罗帕酮Amiodarone 胺碘酮调脂药降脂药HMG-CoA reductase in hibitors HMG-CoA 还原酶抑制剂Nicotinic acid 烟酸Clofibrate 氯贝丁酯抗血小板药物溶栓药recomb inant tissue type plasm inogen activator ,rt-PA 重组组织型纤维蛋白酶原激活剂抗凝药操作interventional therapy for cardiovascular diseases 心血管病介入性治疗Holter ECG mo nitori ng 动态心电图Ultraso und an gioplasty 超声消融术Directi onal coronary atherectomy 定向旋切术High freque ncy rotati onal atherectomy 高频旋磨术Laser an gioplasty激光血管成形术Catheter ablation 心导管消融Radiofreque ncy catheter ablati on 经导管射频消融Percuta neous balloo n mitral valvuloplasty(PBMV) 经皮穿刺球囊二尖瓣成形术Percuta neous balloo n pulm on ic valvuloplasty(PBPV) 经皮穿刺球囊肺动脉瓣成形术Percuta neous tran slu minal septial myocardial ablati on ,(PTSMA) 经皮经腔间隔心肌消融术11Percuta neous tran slu minal coronary an gioplasty (PTCA) 经皮穿刺腔内冠状动脉成形术Percuta neous in tracor onary ste nt impla ntatio n 经皮穿刺冠状动脉内支架安置术Tran slumi nal Extraction catheter (TEC) 经皮血管内切吸导管Artificial cardiac pac ing 人工心脏起搏Multisite cardiac pacing 多部位心脏起搏Biatrial pacing 双心房起搏biventricular pacing 双心室起搏bifocal pacing 双灶起搏Heart tran spla ntatio n 心脏移植An giojet rheolytic thrombectomy 新鲜血栓吸引术Upright tilt-table test ing 直立倾斜试验Impla ntable cardioverter defibrillator (ICD) 置入型心律转复除颤器Thumpversion 捶击复律Cough-version 咳嗽复律Cardioversion心脏电复律Defibrillation心脏电除颤Revascularization 血管重建其它Hemolytic streptococcus 甲族乙型溶血性链球菌Antithymocyte globulin (ATG) 抗胸腺细胞球蛋白Vagus nerve迷走神经,Brainstem death月脑干死亡12Brain death 脑死亡Myocardial remodeli ng 心肌重塑Hemodynamics 血液动力学Atrial natriuretic factor (ANF)心钠素Vasopressin血管加压素,抗利尿激素Bradykinin 缓激肽Triggered activity 触发活动Afterdepolarization 后除极Late ven tricular pote ntial 心室晚电位Si nus n ode recovery time(SNRT) 窦房结恢复时间Sin oatrial co nduction time(SACT) 窦房传导时间In tri nsic heart rate 固有心率Accessory atriove ntricular pathways 房室旁路Atriohisian tracts 房希氏束Nodove ntricular fibers 结-室纤维Fasciculove ntricular fibers 分支室纤维In sulin resista nee 胰岛素抵抗Vasodepressor resp onse 血管减压反应Pulsus tardus 细迟脉Mi nimum In hibitory concen tration (MIC) 最小抑菌浓度Systolic an terior motio n(SAM) (二尖瓣前叶)收缩期前向运动Intermittent claudication 间歇性跛行。
丁苯酞软胶囊联合阿托伐他汀钙片治疗脑梗塞的疗效观察
丁苯酞软胶囊联合阿托伐他汀钙片治疗脑梗塞的疗效观察发布时间:2022-12-02T08:22:13.340Z 来源:《世界复合医学》2022年9期作者:李红丽[导读] 观察应用丁苯酞软胶囊联合阿托伐他汀钙片对脑梗塞患者进行治疗的临床效果。
李红丽哈尔滨市第一医院 150000【摘要】目的观察应用丁苯酞软胶囊联合阿托伐他汀钙片对脑梗塞患者进行治疗的临床效果。
方法研究本院在2019年3月至2020年3月期间收治的78例脑梗塞患者,随机分为参照组与探究组,每组各39例,参照组执行阿托伐他汀钙片对患者进行治疗,探究组执行丁苯酞软胶囊联合阿托伐他汀钙片对患者进行治疗对比两组患者经过治疗后的神经功能缺损情况以及生活能力。
结果探究组患者经过治疗后神经功能缺损情况以及生活能力等各项指标明显优于参照组,差异明显(P<0.05)。
结论在脑梗塞患者的临床治疗中,通过应用丁苯酞软胶囊联合阿托伐他汀钙片对患者进行治疗,可以对患者的神经功能缺损情况进行有效改善,对患者生活能力的提升也具有重要帮助,与单一采用阿托伐他汀钙片治疗相比,效果理想。
【关键词】丁苯酞软胶囊;阿托伐他汀钙片;脑梗塞;疗效[Abstract] Objective To observe the clinical effect of butylphthalide soft capsule combined with atorvastatin calcium tablets on cerebral infarction patients. Methods 78 patients with cerebral infarction admitted to our hospital from March 2019 to March 2020 were randomly divided into the reference group and the exploration group, with 39 patients in each group. The reference group was treated with atorvastatin calcium tablets, and the exploration group was treated with butylphthaline soft capsule combined with atorvastatin calcium tablets. The neurological deficits and living ability of the two groups were compared after treatment. Results after treatment, the neurological function defect and living ability of the patients in the exploration group were significantly better than those in the reference group (P < 0.05). Conclusion in the clinical treatment of patients with cerebral infarction, the combination of butylphthalide soft capsule and atorvastatin calcium tablets can effectively improve the neurological defect of patients, and it is also important to improve the living ability of patients. Compared with the treatment of atorvastatin calcium tablets alone, the effect is ideal. [Key words] butylphthalide soft capsule; Atorvastatin calcium tablets; Cerebral infarction; curative effect脑梗塞这一疾病在临床治疗中,发病原因主要是患者向脑部供血的动脉血管出现堵塞问题,导致患者部分脑组织血液供血量减少,患者部分脑组织出现缺血性坏死或者软化问题【1】。
内质网应激肝癌细胞通过外泌体-Toll样受体4信号途径促进巨噬细胞M2极化
开放科学(资源服务)标识码(OSID):
肝 细 胞 癌 (hepatocellularcarcinoma,HCC)是 全 球第六常见的恶性肿瘤,占癌症相关死因的第四位。 更为棘手的是,在过去的几十年中,肝癌的治疗一直 没有突破。肝脏被认为是人体独特的免疫器官。肝 脏微环境的慢性炎症以及由病毒感染和代谢紊乱引 起的免疫细胞功能异常对肝癌的发展具有重要影 响[1]。从理论上讲,免疫疗法可能为肝癌的治疗带 来新的突破。但是,目前的免疫疗法在肝癌的治疗 中尚未取得令人满意的突破。因此,迫切需要一种 有效的肝癌治疗方法。 恶性肿瘤细胞内外的应激压力如异常增殖、缺 血、缺氧等均可能导致大量错误折叠或未折叠的蛋 白质积聚在内质网腔中,引起内质网应激(endoplas micreticulum stress,ERS)[2]。研究表明,ERS相关 基因或蛋白在多种实体瘤中异常激活,而 ERS的持 续激活与诸如肝癌等多种肿瘤的发生、转移、耐药和 免疫逃逸密切相关[3]。最近,我们发现内质网激活 的肝癌组织可以募集大量高表达免疫抑制分子的巨 噬细胞[4]。巨 噬 细 胞 可 分 为 具 有 抗 肿 瘤 活 性 的 经 典活化 M1型和具有促肿瘤作用的替代活化 M2型。 有报道称,内质网应激增加了肝细胞癌中 GP73的 分泌,GP73参与 TAM 表型有关的细胞因子和趋化 因子的释放[5]。这些结果表明,ERS可能与 HCC微 环境中巨噬细胞的募集以及 M2转化有关,但其潜 在机制仍不清楚。 外泌体是直径为 30-150nm的细胞外囊泡,几 乎所有细胞都可分泌。研究表明,肿瘤细胞可通过 外泌体促使微环境中其他细胞“感知”肿瘤信号,促 进免疫和炎性细胞的表型和功能的变化,从而有利 于肿瘤 免 疫 逃 逸[6]。热 休 克 蛋 白 (heatshockpro tein,HSP)是细胞在热应激、饥饿和缺氧等压力下合 成的一组高度保守的蛋白。HSP70是热休克蛋白家 族的重要成员,也是外泌体的表面标志之一。最近
过氧化物酶体增殖物激活受体
过氧化物酶体增殖物激活受体(PPAR) 是一类由配体激活的核转录因子,属Ⅱ型核受体超家族成员, 存在3种亚型,即PPARα、PPARδ、PPARγ,这三种亚型在结构上有一定的相似性,均含DNA结合区和配体结合区等。
PPAR与配体结合后被激活,与9-顺视黄酸类受体形成异二聚体,然后与靶基因的启动子上游的过氧化物酶体增殖物反应元件(peroxisome proliferator response element,PPRE)结合而发挥转录调控作用。
PPRE 由含相隔一个或两个核苷酸的重复序列AGGTCA组成。
与配体结合后,PPAR在DNA结合区发生变构,进而影响PPAR刺激靶基因转录的能力。
PPARδ几乎在所有组织中表达,浓度低于PPARα及PPARγ,直至最近以前尚未找到此一核受体的选择性配基。
PPARδ是代谢综合征(肥胖、胰岛素抵抗、高血压是与脂质紊乱有关的共同的病态表现)的一个新靶点。
有不少的研究表明:GW501516可作为PPARδ的特异激动剂用于研究。
参考网址:/cjh/2003/shownews.asp?id=156/conference/preview.php?kind_id=03&cat_name=ADA2001&title_id=59219 Regulation of Muscle Fiber Type and Running Endurance by PPARδplos biology,Volume 2 | Issue 10 | October 2004/plosonline/?request=get-document&doi=10.1371%2Fjournal.pbio.0020294NF-KB通路中的抑制剂好像有1.PDTC(pyrrolidine dithiocarbamate),是一种抗氧化剂,主要作用于IκB降解的上游环节(IκBα的磷酸化或IKK的活性水平),2.Gliotoxin 是一种免疫抑制剂,机制可能从多个环节阻断NF-KB的激活,如IκB的降解,NF-KB的核移位和与DNA的结合。
姜黄素二聚体载药纳米粒的制备与性能研究
第51卷第9期2020年9月中南大学学报(自然科学版)Journal of Central South University(Science and Technology)V ol.51No.9Sep.2020姜黄素二聚体载药纳米粒的制备与性能研究文纳川1,刘珍宝2,杜沛芳1,侯姣姣1,刘艳飞1(1.中南大学化学化工学院,湖南长沙,410083;2.中南大学湘雅药学院,湖南长沙,410013)摘要:为了提高抗肿瘤药物姜黄素载药效率,以姜黄素为单元合成新型姜黄素二聚体(CUR2-TK),并以聚乙二醇−聚乳酸羟基乙酸共聚物(PEG-PLGA)为载体,通过单乳液溶剂挥发法,制备姜黄素二聚体缓释纳米粒,研究不同药物CUR2-TK与聚合物PEG-PLGA的质量比(m(CUR2-TK):m(PEG-PLGA))等对纳米粒性能的影响。
研究结果表明:通过姜黄素二聚体构建的载药纳米粒具备极高的载药效率,在m(CUR2-TK):m(PEG-PLGA)为3:1时,载药量和包封率分别达到(61.9±2.9)%和(80.1±3.8)%,且纳米粒形貌规整均一,粒径可控在50~100nm之间,释药时间达4d以上。
关键词:姜黄素二聚体;聚乙二醇聚乳酸羟基乙酸;纳米粒;药物传递体系中图分类号:O633文献标志码:A文章编号:1672-7207(2020)09-2389-07Preparation and properties of curcumin dimer loadednanoparticlesWEN Nachuan1,LIU Zhenbao2,DU Peifang1,HOU Jiaojiao1,LIU Yanfei1(1.School of Chemistry and Chemical Engineering,Central South University,Changsha410083,China;2.Xiangya School of Pharmaceutical Sciences,Central South University,Changsha410013,China)Abstract:In order to improve the drug loading efficiency of antitumor drug curcumin,a new curcumin dimer(CUR2-TK)was synthesized using curcumin as a unit,and polyethylene glycol-polylactic acid-glycolic acid copolymer(PEG-PLGA)used as a carrier,curcumin dimer loaded sustained-release nanoparticles were prepared by a single emulsion solvent volatilization method,and the effects of different experimental conditions such as themass ratio of different drugs to polymer(m(CUR2-TK):m(PEG-PLGA))on the performance of nanoparticles were studied.The results show that the drug-loaded nanoparticles constructed by curcumin dimer have extremely high drug-loading efficiency.Under the condition of m(CUR2-TK):m(PEG-PLGA)=3:1,the drug load and entrapment efficiency reaches(61.9±2.9)%and(80.1±3.8)%,respectively,and the nanoparticles are uniform in appearance DOI:10.11817/j.issn.1672-7207.2020.09.003收稿日期:2020−04−01;修回日期:2020−06−05基金项目(Foundation item):湖南省自然科学基金资助项目(2020JJ4680);湖南省研究生自主探索创新项目(CX20190184);湖湘青年英才项目(2018RS3005);中南大学升华育英计划项目(CX20190242)(Project(2020JJ4680)supported by the Natural Science Foundation of Hunan Province;Project(CX20190184)supported by the Graduate Independent Exploration and Innovation of Hunan Province;Project(2018RS3005)supported by Huxiang Youth Talent;Project(CX20190242)supported by the Sublimation Education of Central South University)通信作者:刘艳飞,博士,副教授,从事药物化学与药物制剂研究;E-mail:*************.cn第51卷中南大学学报(自然科学版)and the particle size can be controlled between 50and 100nm.The drug release of the nanoparticles is up to 4d.Key words:curcumin dimer;PEG-PLGA;nanoparticles;drug delivery system姜黄素(CUR)是一种从姜黄中分离出来的植物化学物质,因其对膀胱癌、肺癌、乳腺癌、宫颈癌、卵巢癌等具有抗肿瘤效果[1−3],以及对正常组织细胞具有低毒性,近年来引起了人们极大的研究兴趣并被广泛用于癌症治疗[4]。
Nanoscale:外泌体样二氧化硅粒子可用做干细胞的超声成像
Nanoscale:外泌体样二氧化硅粒子可用做干细胞的超声成像超声在医学的许多领域中作为关键技术,包括产科、肿瘤学和心脏病学在再生医学中的新兴应用。
然而,超声的一个关键限制因素是靶组织相对于背景的低对比度。
来自美国加利福尼亚大学的研究人员近日在Nanoscale杂志上发表论文,描述了一种新型的杯形二氧化硅纳米粒子,类似于外泌体,并在再生医学成像中对标记的干细胞有显著的超声阻抗不匹配现象。
这些外泌体样的二氧化硅纳米粒子(ELS)是通过乳液模板和二氧化硅前体双-三乙氧基甲硅烷基-乙烷(bis-triethoxysilyl-ethane ,BTSE)和双-3-三甲氧基甲硅烷基丙基-胺(bis-3-trimethoxysilyl-propyl-amine,TSPA)产生的。
研究人员发现40%的TSPA就可以得到外泌体样的形态,以及适合标记间充质干细胞的正电荷。
然后研究人员将这种新结构与超声中使用的其他二氧化硅结构进行比较,包括Stober二氧化硅纳米粒子(Stober silica nanoparticles,SSN)、MCM-41介孔二氧化硅纳米粒子(MCM-41 mesoporous silica nanoparticles,MSN)和介孔泡沫二氧化硅纳米粒子(mesocellular foam silica nanoparticles,MCF),然后发现ELS会造成增强的干细胞信号应答,这是因为其携带的正电荷促进细胞的摄取以及回声反射的增加。
体内检测是用小于500个细胞进行的,在用于标记的浓度下并没有检测到细胞毒性。
利用这种新型结构,研究人员希望外泌体样粒子的成像最终可以在包括药物递送在内的很多应用中得到应用。
图1:通过乳液模板合成的140nm左右的外泌体样粒子图2:粒子标记的MSC在体内的超声成像以及细胞回声反射性的定量参考文献:Chen F, Ma M, Wang J, Wang F, Chern SX, Zhao ER, Jhunjhunwala A, Darmadi S, Chen H, Jokerst JV. Exosome-like silica nanoparticles: a novel ultrasound contrast agent for stem cell imaging. Nanoscale. 2017 Jan 7;9(1):402-411. PubMed PMID: 27924340。
新型肿瘤学疗法!氧化铪纳米颗粒Nbtxr3治疗头颈癌(HNSCC):肿瘤部位激活,总生存期。。。
新型肿瘤学疗法!氧化铪纳⽶颗粒Nbtxr3治疗头颈癌(HNSCC):肿瘤部位激活,总⽣存期。
来源:本站原创 2021-10-28 02:20Nbtxr3具有⼀种物理作⽤机制(MoA),通过放疗激活,在所注射的肿瘤中诱导显著的肿瘤细胞死亡,随后触发适应性免疫反应和长期抗癌记忆。
头颈癌(图⽚来源:)2021年10⽉27⽇讯/⽣物⾕BIOON/ --Nanobiotix是⼀家处于后期临床阶段的⽣物技术公司,致⼒于开创颠覆性的、基于物理的治疗⽅法,为数百万患者带来⾰命性的治疗结果。
近⽇,该公司在2021年美国放射肿瘤学会(ASTRO)年会上公布了先导候选产品Nbtxr3治疗局部晚期头颈部鳞状细胞癌(LA-HNSCC)项⽬的新数据。
Nbtxr3是⼀种新型、潜在的⾸创(first-in-class)肿瘤学产品,由功能化氧化铪纳⽶颗粒组成,通过⼀次性瘤内注射给药,并通过放射激活。
该候选产品的物理作⽤机制(MoA)旨在通过放射激活时,在注射的肿瘤中诱导显著的肿瘤细胞死亡,随后触发适应性免疫反应和长期抗癌记忆。
考虑到物理MoA,Nanobiotix相信Nbtxr3可以扩展到任何可通过放疗治疗的实体肿瘤和任何治疗组合,特别是与免疫检查点抑制剂。
2020年2⽉,美国FDA已授予Nbtxr3快速通道资格(FTD):联⽤或不联⽤西妥昔单抗(cetuximab),⽤于治疗不适合铂类化疗的LA-HNSCC患者。
此次公布的数据来⾃⼀项多中⼼、开放标签、⾮随机、剂量递增和剂量扩展1期研究(Study102 Expansion),该研究正在评估Nbtxr3作为由放疗激活的单⼀药物,治疗不符合顺铂化疗资格且对西妥昔单抗不耐受的难治性⽼年和体弱LA-HNSCC患者的疗效和安全性。
数据显⽰,在可评估⼈群(n=41)中,中位总⽣存期(mOS)为18.1个⽉,中位⽆进展⽣存期(mPFS)为10.6个⽉。
⽽在整个⼈群(所有接受治疗的可评估和不可评估患者;n=54)中,mOS为14.1个⽉,mPFS为9.4个⽉。
(医学课件)超声引导下的神经阻滞
12
探头的准备:
无菌、保证探头与皮肤间无气体存 在
13
仪器:Terason便携超声仪
14
不同组织超声成像特点
动脉 无回声,有搏动
静脉 无回声,可压缩
肌肉 筋膜高回声,肌肉低回升
肌腱 管状高回声线条(纤维状)
20
• 4 超声引导技术 • 实施超声引导进行神经阻滞主要有两种方
式:
• 一是体表标记技术, • 一是实时引导技术。
21
• 超声实时引导技术是进行神经阻滞的最佳方式。 • 操作者手持探头, 寻找到靶神经, 然后便可进针并使其进入
超声声束的轴线。
• 当针邻近神经时, 便可注入局麻药。 • 操作者可清晰地观察到局麻药注射过程, 从而判断局麻药
4
盲法的缺点
• 局麻药毒性反应 • 神经、血管的损伤和气胸 • 过长的神经定位时间和病人不适 • 阻滞失败或者不完全
5
神经刺激器用于神经阻滞的优点
• 阻滞成功的指标客观、明确 • 适用于无法准确说明异感或定位困难病人
(小儿、老年及不合作用镇静药)
• 适度镇静可减少病人的不适感 • 最大程度减少神经损伤 • 成功率较高
• 从此, 超声被用来引导辅助各类神经阻滞操
作,
• 臂丛阻滞、股神经阻滞,坐骨神经阻滞等
17
四 超声引导下神经阻滞
• 1 适应证 • 理论上说对于能在超声仪上成像的各类外周神经
(直径>2mm)均可在超声引导下进行阻滞,
• 尤其是对于以往无法通过解剖或者寻找异感定位
的神经。
• 适用于某些特定人群, 如小儿、肥胖、解剖变异或
磁性氧化铁纳米探针用于肿瘤靶向磁共振成像的研究现状
磁性氧化铁纳米探针用于肿瘤靶向磁共振成像的研究现状黄丹萍【摘要】超顺磁性氧化铁纳米粒子(SPIONs)粒径小,穿透性强,常用于制备分子成像探针或MRI对比剂.近年来,国内外对纳米修饰的肿瘤靶向性磁性氧化铁探针研究越来越多.本文对SPIONs探针的合成、表面修饰及其生物医学应用进展进行综述.%Objective Superparamagnetic iron oxide nanoparticles (SPIONs) has small size and strong penetrativity, which is often used for preparing molecular imaging probe or MR contrast agents. Recently, there are more and more domestic and overseas researches of targeted SPIONs used as probe for imaging of tumor. The synthesis of probes of SPIONs, their surface modification and biomedical application were reviewed in this article.【期刊名称】《中国介入影像与治疗学》【年(卷),期】2012(009)010【总页数】4页(P766-769)【关键词】超顺磁性氧化铁纳米粒;分子探针;磁共振成像;诊断【作者】黄丹萍【作者单位】广州医学院附属广州市第一人民医院放射科,广东广州 510180【正文语种】中文【中图分类】R445.2;R-3分子探针指对某特定生物分子(如蛋白质)具有特异性靶向、并能进行体内或体外示踪的标记物分子,这些分子能够在体或离体反映其靶生物分子的量和功能[1]。
MR分子成像的原理是借助分子探针,通过靶向结合或酶激活的原理及适当策略放大信号,用高分辨力的成像系统检测相应的信号改变,间接反映分子或基因的信息。
细胞外基质金属蛋白酶诱导因子拮抗剂在治疗过度血管发生相关疾病
专利名称:细胞外基质金属蛋白酶诱导因子拮抗剂在治疗过度血管发生相关疾病中的用途
专利类型:发明专利
发明人:M·纳卡达,L·颜,Y·唐
申请号:CN200480043088.X
申请日:20040325
公开号:CN1960753A
公开日:
20070509
专利内容由知识产权出版社提供
摘要:一种用细胞外基质金属蛋白酶诱导因子拮抗剂,通过特异性的防止或抑制新组织形成血管供给的能力,治疗伴有增生性疾病的病理进程例如癌症的方法。
本发明尤其是关于通过使用EMMPRIN拮抗剂如直接针对EMMPRIN的抗体,包括特异部分或变体,特异性针对至少一种EMMPRIN蛋白或其片段,以抑制血管发生的有效剂量来治疗这种疾病的方法。
申请人:森托科尔公司
地址:美国宾夕法尼亚州
国籍:US
代理机构:中国专利代理(香港)有限公司
更多信息请下载全文后查看。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
At the junction of the trapezius and levator scapulae mus-cles (Figures 2 and 3), 5 mL of local anesthetic was injected (2% plain lidocaine) and an insulated nerve-stimulating needle (17-gauge Tuohy needle, Arrow International, USA) was advanced toward the interscalene groove under direct ultra-sound guidance. The needle was guided using an in-plane ultrasound technique until the posterior aspect of the brachialplexus at the C5/C6 level was reached. The bevel of the needle was turned laterally toward the shoulder. The location of the needle tip was further confirmed using a nerve stimulator pro-ducing a 0.5 mA current to evoke a contraction of the muscles innervated by the C5 and C6 roots (biceps, deltoid or triceps twitch). A stimulating catheter was advanced 4 cm to 5 cm beyond the needle tip, making sure that the elicited twitch was sustained at a current of 0.5 mA (Figure 4). Advancement of the catheter, if performed under ultrasound guidance, does not require nerve stimulation; however, it was undertaken for the purposes of the present case series. The needle was then removed and the catheter secured with liquid skin adhesive (Dermabond, Ethicon, USA) and a clear, sterile adhesive dressing. A bolus of 20 mL 0.5% plain ropivacaine was then injected in increments of 5 mL through the catheter after nega-tive aspiration. This was performed under ultrasound guidance to ensure proper spread and to avoid intravascular injection. The entire procedure was timed from the first application of the ultrasound probe (time 0) to the end of local anesthetic injection through the stimulating catheter (time 1). The trans-verse process with which the point of entry was most closely correlated was noted. The distance from the needle to the C6 or C7 transverse process was recorded. The length of the needle and the catheter inserted were also measured. The muscles stimulated by the nerve stimulator and the minimum current in mA were also recorded. The discomfort experienced by patients during the procedure was also measured using a verbal rating scale (VRS) of 0 to 10.An observer evaluated sensory and motor blocks 30 min after the end of injection of local anesthetic solution through the catheter. Asking the patient to flex and extend the forearm at the elbow joint and to abduct the arm at the shoulder joint assessed motor function for the biceps, triceps and deltoid muscles, respectively. Motor function was graded on a scale of 1 to 5, where 1 = no contraction or movement, 2 = weak muscle contraction unable to resist gravity, 3 = weak muscle contraction but able to resist gravity, 4 = resistance againstFigure 1) Patient in position for preparation for the catheterinsertionFigure 2) The needle insertion point for the Boezaart techniqueFigure 3) Ultrasound image showing the junction of the levatorscapulae and trapezius musclesgravity with weak resistance against the examiner and 5 = nor-mal power. Sensory assessment of the C4, C5 and C6 derma-tomes was performed using a blunt 22-gauge needle and was classified on a scale from 1 to 3, where 1 = normal sensation, 2 = sensation of dull pressure and 3 = absence of sensation (anesthesia). The dermatome map was adapted from Hermanns et al (4).All patients received standardized general anesthesia. The total intraoperative narcotic requirement in the operating room was documented. In the postanesthesia care unit (PACU) and on postoperative day 1, patients were assessed for pain scores, the presence of complications and total narcotic requirements.Postoperative analgesia consisted of a continuous infusion of 0.1% plain ropivacaine at a rate of 5 mL/h, as well as oral celecoxib 200 mg twice a day, gabapentin 200 mg three times a day and oxycodone 5 mg to 15 mg as required. The catheter was maintained for 24 h. Patients were also contacted by tele-phone seven days after the surgery, and were assessed for com-plications and level of satisfaction with their anesthetic care.ResultsFigure 4) Ultrasound image showing the catheter emerging from theTuohy needle immediately above the C5 nerve rootBoezaart technique (3) uses a more lateral approach than the Pippa approach, with needle entry at the junction of the leva-tor scapulae and trapezius; however, it may also pass through the levator scapulae (Figure 5). This insertion point corres-ponds to the C6 vertebral level. The modification was designed to minimize the amount of muscle traversed by the needle on its course to the plexus, with the aim of minimizing the pain experienced with needle insertion. We found that passing through the middle scalene muscle and, on occasion, the leva-tor scapulae is unavoidable. It may even be beneficial, by teth-ering the catheter once in situ. This can cause some discomfort, which can be minimized by intravenous fentanyl.In 2005, Sandefo et al (8) published a case series of 120 patients who had brachial plexus catheters inserted using the Boezaart technique. These were shown to provide good analgesia with a peak mean visual analogue scale pain score in the first 48 h of 17 mm. They also showed that this technique could be performed with a low incidence of side effects. Of the 120 patients, only four had Horner’s syndrome and one experi-enced difficulty breathing. Three patients described neck pain, which disappeared once the catheter was removed. This inci-dence of neck pain corresponds with Boezaart et al’s experience in 2003 (3). None of our patients reported neck pain when they were contacted seven days postoperatively. In 2006, Rettig et al (9) published a trial comparing the Pippa approach with the Winnie approach. They found no significant differ-ence in the success rate of the block or in the complications associated with either block. They used an 80 mm insulated block needle for this technique. The use of a sharp needle in place of a large-gauge loss-of-resistance needle for a paraverte-bral block was criticized (10). This was due to the proximity of the approach to the dural cuffs and the risk of intrathecal injec-tion. This is interesting, given that Pippa was using a 21-gauge needle in his description of the block (2).Figure 5) Cross-section of the neck at C6 with the needle pathwaysuperimposed. Adapted from reference 13。